STAT-related	O
transcription	B-protein
factors	I-protein
are	O
constitutively	O
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
acute	O
leukemia	O
patients	O
.	O

A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	B-protein
has	O
recently	O
been	O
elaborated	O
.	O

The	O
JAK	B-protein
kinases	I-protein
and	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	B-protein
factors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
acute	O
leukemia	O
.	O

We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta-casein	B-DNA
and	I-DNA
IRF-1	I-DNA
gene	I-DNA
promoters	I-DNA
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	B-protein
proteins	I-protein
in	O
nuclear	O
extracts	O
from	O
acute	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
in	O
bandshift	O
assays	O
.	O

Specific	O
DNA	O
protein	B-protein
complex	I-protein
formation	O
was	O
observed	O
with	O
the	O
probes	O
from	O
the	O
beta-casein	O
and	O
IRF-1	B-DNA
gene	I-DNA
promoters	I-DNA
,	O
but	O
not	O
with	O
the	O
ISRE	O
oligonucleotide	O
probe	O
,	O
when	O
cell	O
extracts	O
from	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
were	O
investigated	O
.	O

We	O
used	O
nonradioactive	O
oligonucleotides	O
as	O
competitors	O
to	O
show	O
the	O
specificity	O
of	O
the	O
complex	O
formation	O
.	O

Specific	O
antibodies	B-protein
directed	O
against	O
the	O
individual	O
STAT	B-protein
proteins	I-protein
were	O
used	O
in	O
supershift	O
experiments	O
.	O

STAT5-	B-protein
and	I-protein
STAT1-related	I-protein
factors	I-protein
were	O
detected	O
in	O
ALL	O
and	O
STAT1-	B-protein
,	I-protein
STAT3-	I-protein
,	I-protein
and	I-protein
STAT5-related	I-protein
proteins	I-protein
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

Since	O
the	O
cells	O
were	O
not	O
treated	O
with	O
cytokines	B-protein
before	O
the	O
nuclear	B-protein
proteins	I-protein
were	O
extracted	O
,	O
we	O
conclude	O
that	O
these	O
factors	O
are	O
constitutively	O
activated	O
in	O
vivo	O
.	O

It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RAPID	NULL
COMMUNICATION	NULL
STAT-Related	NULL
Transcription	NULL
Factors	NULL
Are	NULL
Constitutively	NULL
Activated	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Cells	NULL
From	NULL
Acute	NULL
Leukemia	NULL
Patients	NULL
By	NULL
Valérie	NULL
Gouilleux-Gruart	NULL
,	NULL
Fabrice	NULL
Gouilleux	NULL
,	NULL
Corinne	NULL
Desaint	NULL
,	NULL
Jean-Frangois	NULL
Claisse	NULL
,	NULL
Jean-Claude	NULL
Capiod	NULL
,	NULL
Jacques	NULL
Delobel	NULL
,	NULL
Renate	NULL
Weber-Nordt	NULL
,	NULL
Isabelle	NULL
Dusanter-Fourt	NULL
,	NULL
Frangois	NULL
Dreyfus	NULL
,	NULL
Bernd	NULL
Groner	NULL
,	NULL
and	NULL
Lionel	NULL
Prin	NULL
A	NULL
signal	NULL
transduction	NULL
pathway	NULL
activated	NULL
by	NULL
many	NULL
cytokines	NULL
has	NULL
recently	NULL
been	NULL
elaborated	NULL
.	NULL

The	NULL
JAK	NULL
kinases	NULL
and	NULL
the	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
factors	NULL
have	NULL
been	NULL
found	NULL
to	NULL
be	NULL
essential	NULL
components	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
describe	NULL
the	NULL
presence	NULL
of	NULL
constitutively	NULL
activated	NULL
STAT	NULL
factors	NULL
in	NULL
peripheral	NULL
blood	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
.	NULL

We	NULL
used	NULL
oligonucleotide	NULL
probes	NULL
from	NULL
the	NULL
B-casein	NULL
and	NULL
IRF-1	NULL
gene	NULL
promoters	NULL
and	NULL
the	NULL
ISRE	NULL
probe	NULL
to	NULL
detect	NULL
STAT	NULL
proteins	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
acute	NULL
leukemia	NULL
cells	NULL
in	NULL
bandshift	NULL
assays	NULL
.	NULL

Specific	NULL
DNA	NULL
protein	NULL
complex	NULL
formation	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
probes	NULL
from	NULL
the	NULL
B-casein	NULL
and	NULL
IRF-1	NULL
gene	NULL
promoters	NULL
,	NULL
but	NULL
not	NULL
with	NULL
the	NULL
ISRE	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
when	NULL
cell	NULL
extracts	NULL
from	NULL
acute	NULL
lymphoblastic	NULL
leuke-	NULL
EVELOPMENT	NULL
,	NULL
maintenance	NULL
,	NULL
and	NULL
functional	NULL
activation	NULL
of	NULL
immune	NULL
surveillance	NULL
and	NULL
effector	NULL
cells	NULL
are	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
wide	NULL
spectrum	NULL
of	NULL
interleukins	NULL
(	NULL
ILs	NULL
)	NULL
,	NULL
growth	NULL
factors	NULL
,	NULL
and	NULL
hormones	NULL
.	NULL

The	NULL
interaction	NULL
of	NULL
a	NULL
cytokine	NULL
with	NULL
its	NULL
receptor	NULL
triggers	NULL
specific	NULL
events	NULL
such	NULL
as	NULL
gene	NULL
tran-scription	NULL
,	NULL
protein	NULL
expression	NULL
,	NULL
and	NULL
release	NULL
leading	NULL
either	NULL
to	NULL
differentiation	NULL
or	NULL
proliferation	NULL
depending	NULL
on	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
STAT	NULL
proteins	NULL
are	NULL
a	NULL
new	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
cytokine	NULL
,	NULL
growth	NULL
factor	NULL
,	NULL
and	NULL
hormone	NULL
signal	NULL
transduction	NULL
.	NULL

'~	NULL
``	NULL
Cytokine	NULL
binding	NULL
to	NULL
their	NULL
receptors	NULL
leads	NULL
to	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
associated	NULL
cytoplasmic	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

These	NULL
kinases	NULL
belong	NULL
to	NULL
the	NULL
JAK	NULL
fam-ily	NULL
.	NULL

JAKs	NULL
phosphorylate	NULL
STAT	NULL
proteins	NULL
,	NULL
and	NULL
STAT	NULL
proteins	NULL
dimerize	NULL
and	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
they	NULL
bind	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
in	NULL
promoter	NULL
regions	NULL
of	NULL
responsive	NULL
genes	NULL
.	NULL
``	NULL

Different	NULL
members	NULL
of	NULL
the	NULL
STAT	NULL
factor	NULL
family	NULL
have	NULL
been	NULL
cloned	NULL
and	NULL
the	NULL
cytokines	NULL
and	NULL
hormones	NULL
stimulating	NULL
their	NULL
activation	NULL
have	NULL
been	NULL
studied	NULL
.	NULL

p91-Statl	NULL
constitutes	NULL
the	NULL
inter-feron-y	NULL
-	NULL
(	NULL
IFN-y	NULL
)	NULL
-activated	NULL
transcription	NULL
factor	NULL
,	NULL
°	NULL
p91-STAT1	NULL
,	NULL
and	NULL
pl13-STAT2	NULL
together	NULL
with	NULL
the	NULL
p48	NULL
subunit	NULL
constitute	NULL
the	NULL
IFN-	NULL
«	NULL
/	NULL
$	NULL
responsive	NULL
transcription	NULL
factor	NULL
(	NULL
ISGF-3	NULL
)	NULL
.	NULL

``	NULL
*	NULL
APRF-STAT3	NULL
is	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
,	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
EGF	NULL
)	NULL
,	NULL
IL-12	NULL
and	NULL
granulocyte	NULL
From	NULL
Laboratoire	NULL
d'Immunologie	NULL
and	NULL
Laboratoire	NULL
d'Hématolo-gie	NULL
,	NULL
Centre	NULL
Hospitalier	NULL
Universitaire	NULL
d'Amiens	NULL
,	NULL
Amiens	NULL
,	NULL
France	NULL
;	NULL
Institute	NULL
for	NULL
Experimental	NULL
Cancer	NULL
Research	NULL
,	NULL
Tumor	NULL
Biology	NULL
Center	NULL
,	NULL
Freiburg	NULL
;	NULL
the	NULL
Department	NULL
of	NULL
Hematology	NULL
and	NULL
Oncology	NULL
,	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Freiburg	NULL
,	NULL
Germany	NULL
:	NULL
;	NULL
and	NULL
Hopital	NULL
Cochin	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
.	NULL

Submitted	NULL
September	NULL
18	NULL
,	NULL
1995	NULL
;	NULL
accepted	NULL
December	NULL
18	NULL
,	NULL
1995	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Valérie	NULL
Gouilleux-Gruart	NULL
,	NULL
PhD	NULL
,	NULL
Laboratoire	NULL
d	NULL
'	NULL
Immunologie	NULL
,	NULL
Centre	NULL
Hospitalier	NULL
Universitaire	NULL
d'Amiens	NULL
,	NULL
Place	NULL
Victor	NULL
Pauchet	NULL
,	NULL
80054	NULL
Amiens	NULL
cedex	NULL
1	NULL
,	NULL
France	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/96/8705-0054	NULL
$	NULL
3.00/0	NULL
1692	NULL
mia	NULL
(	NULL
ALL	NULL
)	NULL
and	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
(	NULL
AML	NULL
)	NULL
were	NULL
investigated	NULL
.	NULL

We	NULL
used	NULL
nonradioactive	NULL
oligonucleotides	NULL
as	NULL
competitors	NULL
to	NULL
show	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
complex	NULL
formation	NULL
.	NULL

Specific	NULL
antibodies	NULL
directed	NULL
against	NULL
the	NULL
individual	NULL
STAT	NULL
proteins	NULL
were	NULL
used	NULL
in	NULL
supershift	NULL
experiments	NULL
.	NULL

STAT5-	NULL
and	NULL
STATi-related	NULL
factors	NULL
were	NULL
detected	NULL
in	NULL
ALL	NULL
and	NULL
STAT1-	NULL
,	NULL
STAT3-	NULL
,	NULL
and	NULL
STAT5-related	NULL
proteins	NULL
were	NULL
present	NULL
in	NULL
nuclear	NULL
cell	NULL
extracts	NULL
from	NULL
AML	NULL
.	NULL

Since	NULL
the	NULL
cells	NULL
were	NULL
not	NULL
treated	NULL
with	NULL
cytokines	NULL
before	NULL
the	NULL
nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
these	NULL
factors	NULL
are	NULL
constitutively	NULL
activated	NULL
in	NULL
vivo	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
STAT	NULL
proteins	NULL
is	NULL
a	NULL
part	NULL
of	NULL
the	NULL
events	NULL
of	NULL
leukemogenesis	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
,	NULL
``	NULL
*	NULL
``	NULL
STAT4	NULL
in	NULL
response	NULL
to	NULL
IL-12	NULL
.	NULL
'	NULL

''	NULL
``	NULL
Prolactin	NULL
,	NULL
IL-3	NULL
,	NULL
WL-5	NULL
,	NULL
granulocyte-macrophage	NULL
(	NULL
GM	NULL
)	NULL
-CSF	NULL
,	NULL
growth	NULL
hormone	NULL
(	NULL
GH	NULL
)	NULL
,	NULL
IL-2	NULL
,	NULL
thrombopoietin	NULL
,	NULL
and	NULL
erythropoietin	NULL
cause	NULL
MGF-STATS	NULL
activation	NULL
.	NULL

'*	NULL
``	NULL
°	NULL
Two	NULL
highly	NULL
related	NULL
STATS	NULL
proteins	NULL
,	NULL
STAT	NULL
Sa	NULL
and	NULL
STATS5b	NULL
,	NULL
have	NULL
been	NULL
described	NULL
.	NULL

Their	NULL
expression	NULL
is	NULL
tissue	NULL
specifically	NULL
regu-lated	NULL
.	NULL
``	NULL

STAT6	NULL
is	NULL
mainly	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IL-4	NULL
and	NULL
IL_3.23,24	NULL
Because	NULL
cytokines	NULL
not	NULL
only	NULL
regulate	NULL
the	NULL
differentiation	NULL
of	NULL
the	NULL
cells	NULL
but	NULL
also	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
proliferation	NULL
,	NULL
it	NULL
is	NULL
reasonable	NULL
to	NULL
assume	NULL
that	NULL
aberrations	NULL
in	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
tumor	NULL
formation	NULL
.	NULL

Several	NULL
observations	NULL
support	NULL
this	NULL
hypothesis	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
an	NULL
amino	NULL
acid	NULL
substitution	NULL
in	NULL
the	NULL
Drosophilia	NULL
homolog	NULL
of	NULL
the	NULL
JAK	NULL
kinase	NULL
gene	NULL
causes	NULL
leukemia-like	NULL
hematopoietic	NULL
defects	NULL
.	NULL
``	NULL

Overactivity	NULL
of	NULL
the	NULL
mutated	NULL
protein	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
malignant	NULL
neoplasia	NULL
.	NULL
``	NULL

''	NULL
Recently	NULL
,	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
has	NULL
been	NULL
described	NULL
in	NULL
T	NULL
cells	NULL
transformed	NULL
with	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus-1	NULL
(	NULL
HTLV-1	NULL
)	NULL
.	NULL

IL-2-independent	NULL
growth	NULL
acquired	NULL
by	NULL
cells	NULL
transformed	NULL
with	NULL
HTLV-1	NULL
correlates	NULL
to	NULL
acquisition	NULL
of	NULL
the	NULL
constitutively	NULL
activated	NULL
JAK-STAT	NULL
path-way	NULL
.	NULL
``	NULL

We	NULL
examined	NULL
whether	NULL
constitutively	NULL
activated	NULL
STAT	NULL
proteins	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
cells	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
hematologic	NULL
malignancies	NULL
.	NULL

We	NULL
derived	NULL
nuclear	NULL
extracts	NULL
from	NULL
acute	NULL
leukemia	NULL
cells	NULL
and	NULL
analyzed	NULL
them	NULL
in	NULL
bandshift	NULL
assays	NULL
by	NULL
using	NULL
specific	NULL
oligonucleotide	NULL
probes	NULL
and	NULL
antibodies	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Patients	NULL
.	NULL

Three	NULL
patients	NULL
with	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
(	NULL
ALL	NULL
)	NULL
,	NULL
five	NULL
patients	NULL
with	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
(	NULL
AML	NULL
)	NULL
,	NULL
and	NULL
three	NULL
controls	NULL
were	NULL
investigated	NULL
.	NULL

Diagnosis	NULL
was	NULL
established	NULL
according	NULL
to	NULL
French-	NULL
American-British	NULL
(	NULL
FAB	NULL
)	NULL
classification	NULL
``	NULL
``	NULL
and	NULL
associated	NULL
with	NULL
immunologic	NULL
and	NULL
genetic	NULL
studies	NULL
on	NULL
peripheral	NULL
blood	NULL
(	NULL
PB	NULL
)	NULL
and	NULL
bone	NULL
marrow	NULL
(	NULL
BM	NULL
)	NULL
.	NULL

Cells	NULL
.	NULL

The	NULL
total	NULL
leukocyte	NULL
population	NULL
was	NULL
collected	NULL
after	NULL
PB	NULL
sample	NULL
sedimentation	NULL
.	NULL

Plasma	NULL
enriched	NULL
cells	NULL
were	NULL
centrifuged	NULL
at	NULL
400g	NULL
at	NULL
4°C	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
.	NULL

When	NULL
mentioned	NULL
,	NULL
mononuclear	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
the	NULL
Ficoll	NULL
(	NULL
Techgen	NULL
,	NULL
Les	NULL
Ulis	NULL
,	NULL
France	NULL
)	NULL
sedimentation	NULL
procedure	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
87	NULL
,	NULL
No	NULL
5	NULL
(	NULL
March	NULL
1	NULL
)	NULL
,	NULL
1996	NULL
:	NULL
pp	NULL
1692-1697	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

STAT-RELATED	NULL
FACTORS	NULL
IN	NULL
ACUTE	NULL
LEUKEMIA	NULL
1693	NULL
Table	NULL
1	NULL
.	NULL

Clinical	NULL
Characteristics	NULL
of	NULL
the	NULL
Patients	NULL
1	NULL
to	NULL
4	NULL
Patient	NULL
No	NULL
.	NULL

Age	NULL
Type	NULL
White	NULL
Blood	NULL
Cell	NULL
N	NULL
Eo	NULL
B	NULL
Le	NULL
M	NULL
BI	NULL
Cytogenetic	NULL
Counts	NULL
10°/L	NULL
(	NULL
%	NULL
)	NULL
1	NULL
27	NULL
ALL	NULL
188	NULL
4	NULL
0	NULL
0	NULL
8	NULL
1	NULL
87	NULL
1	NULL
(	NULL
9	NULL
;	NULL
22	NULL
)	NULL
2	NULL
66	NULL
M1	NULL
AML	NULL
99	NULL
4	NULL
0	NULL
1	NULL
8	NULL
2	NULL
85	NULL
ND	NULL
3	NULL
26	NULL
ALL	NULL
11,3	NULL
10	NULL
0	NULL
0	NULL
13	NULL
2	NULL
70	NULL
Complex	NULL
abnormalities	NULL
4	NULL
68	NULL
M5	NULL
AML	NULL
23,6	NULL
14	NULL
1	NULL
0	NULL
8	NULL
0	NULL
77	NULL
ND	NULL
Abbreviations	NULL
:	NULL
N	NULL
,	NULL
neutrophil	NULL
;	NULL
Eo	NULL
,	NULL
eosinophil	NULL
;	NULL
B	NULL
,	NULL
basophil	NULL
;	NULL
Le	NULL
,	NULL
lymphocyte	NULL
;	NULL
M	NULL
,	NULL
monocyte	NULL
;	NULL
BI	NULL
,	NULL
blast	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

Preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
bandshift	NULL
assays	NULL
.	NULL

-	NULL
Cells	NULL
were	NULL
resuspended	NULL
in	NULL
lysis	NULL
buffer	NULL
containing	NULL
10	NULL
mmol/L	NULL
HEPES	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
mmol/L	NULL
KCI	NULL
,	NULL
1.5	NULL
mmol/L	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
%	NULL
NP4O0	NULL
,	NULL
5	NULL
ug/mL	NULL
leupeptin	NULL
,	NULL
5	NULL
g/mL	NULL
aprotinin	NULL
,	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
0.5	NULL
mmol/L	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
1	NULL
mmol/L	NULL
phenyImethyIsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
and	NULL
left	NULL
at	NULL
4°C	NULL
for	NULL
8	NULL
minutes	NULL
.	NULL

After	NULL
centrifugation	NULL
at	NULL
14,000	NULL
rpm	NULL
for	NULL
2	NULL
minutes	NULL
,	NULL
the	NULL
supernatants	NULL
were	NULL
discarded	NULL
and	NULL
nuclei	NULL
were	NULL
extracted	NULL
with	NULL
50	NULL
uL	NULL
hypertonic	NULL
buffer	NULL
containing	NULL
20	NULL
mmol/L	NULL
HEPES	NULL
pH	NULL
7.9	NULL
,	NULL
420	NULL
mmol/	NULL
L	NULL
NaCl	NULL
,	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
5	NULL
g/mL	NULL
leupeptin	NULL
,	NULL
5	NULL
ug/	NULL
mL	NULL
aprotinin	NULL
,	NULL
0.5	NULL
mmol/L	NULL
DTT	NULL
,	NULL
1	NULL
mmol/L	NULL
PMSF	NULL
,	NULL
and	NULL
100	NULL
pmol/	NULL
L	NULL
vanadate	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
centrifuged	NULL
at	NULL
14,000	NULL
rpm	NULL
for	NULL
5	NULL
minutes	NULL
at	NULL
4°C	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
used	NULL
for	NULL
bandshift	NULL
experiments	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

The	NULL
autoradio-graphs	NULL
were	NULL
exposed	NULL
for	NULL
20	NULL
hours	NULL
to	NULL
4	NULL
days	NULL
in	NULL
AML	NULL
analysis	NULL
.	NULL

Oligonucleotide	NULL
probes	NULL
.	NULL

The	NULL
gamma	NULL
activated	NULL
site	NULL
(	NULL
GAS	NULL
)	NULL
sequence	NULL
present	NULL
in	NULL
the	NULL
IRF-1	NULL
gene	NULL
promoter	NULL
(	NULL
5'-GATCCATTTCCC-CGAAATGA-3	NULL
``	NULL
)	NULL
,	NULL
the	NULL
MGF	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
bovine	NULL
3-casein	NULL
gene	NULL
promoter	NULL
-	NULL
(	NULL
5-AGATTTCTAGGAATTCAAATC-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
ISRE	NULL
present	NULL
in	NULL
ISG-15	NULL
gene	NULL
promoter	NULL
ACCGAAACTGAAGCC-3	NULL
'	NULL
)	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
in	NULL
bandshift	NULL
assays	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
end-labeled	NULL
with	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
P	NULL
adenosine	NULL
triphosphate	NULL
(	NULL
ATP	NULL
)	NULL
.	NULL

The	NULL
following	NULL
oligonucleotides	NULL
were	NULL
used	NULL
in	NULL
competition	NULL
experiments	NULL
:	NULL
GAS	NULL
element	NULL
present	NULL
in	NULL
the	NULL
Ly-6E	NULL
gene	NULL
:	NULL
5-CATGTTATGCATATTCCTGTA-AGTG-3	NULL
'	NULL
.	NULL

GAS	NULL
sequence	NULL
from	NULL
the	NULL
FeyRI	NULL
gene	NULL
:	NULL
5-GTATTTCCC-AGAAAAGGAAC-3	NULL
'	NULL
.	NULL

FeeRIIb	NULL
:	NULL
5-GAATTTCTAAGAAAGGGA-3	NULL
'	NULL
.	NULL

Ie	NULL
:	NULL
5-GTCAACTTCCCAAGAACAGAA-3	NULL
'	NULL
.	NULL

GAS	NULL
sequence	NULL
in	NULL
GBP	NULL
:	NULL
5-AAGTACTTTCAGTTTCATATTACTCTAAATC-3	NULL
'	NULL
.	NULL

APRE	NULL
from	NULL
the	NULL
a2-macroglobulin	NULL
gene	NULL
:	NULL
AATTC	NULL
CTA-3	NULL
'	NULL
.	NULL

SIEm67	NULL
from	NULL
the	NULL
Fos	NULL
gene	NULL
promoter	NULL
:	NULL
5'-CAT-TTCCCGTAAATC-3	NULL
'	NULL
.	NULL

Antibodies	NULL
.	NULL

-	NULL
Anti-STATl	NULL
antibody	NULL
was	NULL
purchased	NULL
from	NULL
UBI	NULL
(	NULL
Washington	NULL
,	NULL
DC	NULL
)	NULL
.	NULL

Three	NULL
anti-STAT3	NULL
antibodies	NULL
were	NULL
tested	NULL
:	NULL
the	NULL
anti-STAT3	NULL
(	NULL
30C	NULL
)	NULL
provided	NULL
by	NULL
D.	NULL
Levy	NULL
(	NULL
New	NULL
York	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
)	NULL
,	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C-20	NULL
)	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
,	NULL
and	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C	NULL
)	NULL
from	NULL
J.	NULL
Darnell	NULL
(	NULL
Rockfeller	NULL
Uni-versity	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

He	NULL
also	NULL
provided	NULL
the	NULL
anti-STAT2	NULL
and	NULL
anti-STAT4	NULL
antisera	NULL
.	NULL

Anti-STATS	NULL
antiserum	NULL
has	NULL
been	NULL
produced	NULL
in	NULL
chickens	NULL
.	NULL
``	NULL

RESULTS	NULL
Nuclear	NULL
proteins	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
bind	NULL
to	NULL
distinct	NULL
GAS	NULL
elements	NULL
.	NULL

-	NULL
To	NULL
analyze	NULL
the	NULL
presence	NULL
of	NULL
constitutively	NULL
activated	NULL
STATs	NULL
in	NULL
leukemic	NULL
cells	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
total	NULL
leukocytes	NULL
were	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
ALL	NULL
(	NULL
nos	NULL
.	NULL

1	NULL
and	NULL
3	NULL
)	NULL
,	NULL
AML	NULL
(	NULL
nos	NULL
.	NULL

2	NULL
and	NULL
4	NULL
,	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
and	NULL
from	NULL
controls	NULL
.	NULL

Three	NULL
different	NULL
probes	NULL
were	NULL
used	NULL
in	NULL
the	NULL
bandshift	NULL
assays	NULL
:	NULL
(	NULL
1	NULL
)	NULL
the	NULL
GAS	NULL
sequence	NULL
present	NULL
in	NULL
IRF-1	NULL
gene	NULL
promoter	NULL
and	NULL
able	NULL
to	NULL
bind	NULL
STAT	NULL
1	NULL
,	NULL
STAT3	NULL
,	NULL
and	NULL
STATS	NULL
;	NULL
(	NULL
2	NULL
)	NULL
the	NULL
/3-casein	NULL
promoter	NULL
oligonucleotide	NULL
probe	NULL
able	NULL
to	NULL
bind	NULL
STATS	NULL
with	NULL
high	NULL
affinity	NULL
and	NULL
STAT1	NULL
,	NULL
STAT3	NULL
,	NULL
STAT6	NULL
with	NULL
a	NULL
lower	NULL
affinity	NULL
;	NULL
and	NULL
(	NULL
3	NULL
)	NULL
the	NULL
ISRE	NULL
sequence	NULL
recognized	NULL
by	NULL
ISGF3a	NULL
complex	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
1A	NULL
,	NULL
a	NULL
STAT	NULL
DNA-binding	NULL
complex	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
IRF-1	NULL
and	NULL
the	NULL
3-casein	NULL
oligonucleotide	NULL
probes	NULL
and	NULL
cell	NULL
extracts	NULL
from	NULL
the	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
(	NULL
lanes	NULL
a	NULL
through	NULL
h	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
was	NULL
not	NULL
formed	NULL
with	NULL
cell	NULL
extracts	NULL
from	NULL
controls	NULL
(	NULL
Fig	NULL
1B	NULL
,	NULL
lanes	NULL
Probe	NULL
:	NULL
RB-casein	NULL
IRF-1	NULL
ISRE	NULL
Patient	NULL
n°	NULL
1	NULL
2	NULL
3	NULL
4	NULL
1	NULL
2	NULL
3	NULL
4	NULL
1	NULL
2	NULL
3	NULL
4	NULL
amt	NULL
noon	NULL
a	NULL
b	NULL
c	NULL
d	NULL
e	NULL
f	NULL
g	NULL
h	NULL
ij	NULL
kd	NULL
Probe	NULL
:	NULL
B-casein	NULL
IRF-1	NULL
Control	NULL
n°	NULL
5	NULL
6	NULL
7	NULL
5	NULL
'	NULL
6	NULL
7	NULL
B	NULL
link	NULL
.	NULL

L4	NULL
m	NULL
n	NULL
o	NULL
p	NULL
q	NULL
or	NULL
Patient	NULL
n°	NULL
2	NULL
2	NULL
4	NULL
4	NULL
-	NULL
»	NULL
bub	NULL
(	NULL
0	NULL
L	NULL
al	NULL
dud	NULL
s	NULL
t	NULL
u	NULL
v	NULL
Fig	NULL
1	NULL
.	NULL

Bandshift	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
leukocytes	NULL
isolated	NULL
from	NULL
PB	NULL
of	NULL
patients	NULL
(	NULL
A	NULL
)	NULL
with	NULL
ALL	NULL
(	NULL
patients	NULL
1	NULL
and	NULL
3	NULL
)	NULL
,	NULL
AML	NULL
(	NULL
patients	NULL
2	NULL
and	NULL
4	NULL
)	NULL
,	NULL
and	NULL
controls	NULL
5	NULL
to	NULL
7	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
protein	NULL
was	NULL
introduced	NULL
into	NULL
each	NULL
binding	NULL
reaction	NULL
and	NULL
incubated	NULL
with	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lanes	NULL
a	NULL
through	NULL
d	NULL
,	NULL
m	NULL
through	NULL
0	NULL
}	NULL
,	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lanes	NULL
e	NULL
through	NULL
h	NULL
,	NULL
p	NULL
through	NULL
r	NULL
)	NULL
,	NULL
or	NULL
ISRE	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lanes	NULL
i	NULL
through	NULL
I	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Comparison	NULL
of	NULL
DNA-protein	NULL
complexes	NULL
formed	NULL
either	NULL
with	NULL
total	NULL
leukocyte	NULL
proteins	NULL
(	NULL
lanes	NULL
s	NULL
and	NULL
u	NULL
)	NULL
or	NULL
with	NULL
mononuclear	NULL
cell	NULL
proteins	NULL
(	NULL
lanes	NULL
t	NULL
and	NULL
v	NULL
)	NULL
from	NULL
patients	NULL
2	NULL
(	NULL
lanes	NULL
s	NULL
and	NULL
t	NULL
)	NULL
and	NULL
4	NULL
(	NULL
lanes	NULL
u	NULL
and	NULL
v	NULL
)	NULL
in	NULL
bandshift	NULL
assays	NULL
.	NULL

The	NULL
IRF-1	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1694	NULL
GOUILLEUX-GRUART	NULL
ET	NULL
AL	NULL
Table	NULL
2	NULL
.	NULL

Analysis	NULL
of	NULL
STAT	NULL
DNA-Binding	NULL
Activities	NULL
in	NULL
Nuclear	NULL
Extracts	NULL
From	NULL
Patients	NULL
With	NULL
Acute	NULL
Leukemia	NULL
Patient	NULL
No	NULL
.	NULL

Type	NULL
STAT	NULL
DNA-Binding	NULL
Activity*	NULL
Anti	NULL
STAT1t	NULL
Anti	NULL
STAT2t	NULL
Anti	NULL
STAT3t	NULL
Anti	NULL
STAT4t	NULL
Anti	NULL
STAT5t	NULL
1	NULL
ALL	NULL
+	NULL
-	NULL
+	NULL
2	NULL
M1	NULL
AML	NULL
+	NULL
+	NULL
3	NULL
ALL	NULL
+	NULL
4	NULL
M5	NULL
AML	NULL
+	NULL
R	NULL
x	NULL
5	NULL
M5	NULL
AML	NULL
+	NULL
+	NULL
6	NULL
M4	NULL
AML	NULL
+	NULL
+	NULL
4	NULL
7	NULL
M4	NULL
AML	NULL
+	NULL
ND	NULL
ND	NULL
+	NULL
ND	NULL
8	NULL
ALL	NULL
+	NULL
+	NULL
ND	NULL
ND	NULL
+	NULL
Abbreviation	NULL
:	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

®	NULL
Formation	NULL
of	NULL
DNA-binding	NULL
complex	NULL
in	NULL
presence	NULL
of	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

t	NULL
Absence	NULL
or	NULL
presence	NULL
of	NULL
the	NULL
STAT	NULL
related	NULL
factor	NULL
in	NULL
the	NULL
DNA-binding	NULL
complex	NULL
incubated	NULL
with	NULL
the	NULL
corresponding	NULL
anti-STAT	NULL
antibody	NULL
.	NULL

m	NULL
through	NULL
r	NULL
)	NULL
.	NULL

No	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
ISRE	NULL
probe	NULL
and	NULL
cell	NULL
extracts	NULL
from	NULL
patients	NULL
(	NULL
lanes	NULL
i	NULL
through	NULL
1	NULL
)	NULL
.	NULL

The	NULL
DNA-binding	NULL
complexes	NULL
formed	NULL
by	NULL
the	NULL
cell	NULL
extracts	NULL
from	NULL
the	NULL
two	NULL
patients	NULL
with	NULL
ALL	NULL
(	NULL
nos	NULL
.	NULL

1	NULL
and	NULL
3	NULL
)	NULL
yielded	NULL
a	NULL
stronger	NULL
signal	NULL
when	NULL
compared	NULL
to	NULL
those	NULL
formed	NULL
by	NULL
the	NULL
cell	NULL
extracts	NULL
from	NULL
patients	NULL
with	NULL
AML	NULL
(	NULL
nos	NULL
.	NULL

2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
was	NULL
introduced	NULL
onto	NULL
the	NULL
complex	NULL
formation	NULL
.	NULL

We	NULL
separated	NULL
the	NULL
mononuclear	NULL
cell	NULL
fraction	NULL
containing	NULL
the	NULL
blast	NULL
population	NULL
from	NULL
polymorphonuclear	NULL
cells	NULL
(	NULL
neutrophils	NULL
,	NULL
eosinophils	NULL
,	NULL
and	NULL
basophils	NULL
represent	NULL
between	NULL
4	NULL
%	NULL
and	NULL
15	NULL
%	NULL
of	NULL
leukocytes	NULL
in	NULL
patients	NULL
1	NULL
to	NULL
4	NULL
,	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
by	NULL
Ficoll	NULL
gradient	NULL
centrifugation	NULL
.	NULL

The	NULL
bandshift	NULL
with	NULL
the	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
and	NULL
proteins	NULL
from	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
2	NULL
and	NULL
4	NULL
are	NULL
presented	NULL
in	NULL
Fig	NULL
1C	NULL
.	NULL

The	NULL
DNA-binding	NULL
complex	NULL
present	NULL
in	NULL
total	NULL
leukocytes	NULL
(	NULL
lanes	NULL
s	NULL
and	NULL
u	NULL
)	NULL
was	NULL
still	NULL
detectable	NULL
when	NULL
nuclear	NULL
proteins	NULL
from	NULL
purified	NULL
mononuclear	NULL
cells	NULL
(	NULL
blast	NULL
population	NULL
)	NULL
were	NULL
used	NULL
(	NULL
lanes	NULL
t	NULL
and	NULL
v	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
before	NULL
and	NULL
after	NULL
cell	NULL
separation	NULL
.	NULL

This	NULL
excludes	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
cell	NULL
manipulation	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
results	NULL
.	NULL

A	NULL
band	NULL
with	NULL
slower	NULL
mobility	NULL
is	NULL
present	NULL
in	NULL
nuclear	NULL
cell	NULL
extracts	NULL
from	NULL
patients	NULL
3	NULL
and	NULL
4	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
lanes	NULL
c	NULL
,	NULL
d	NULL
,	NULL
g	NULL
,	NULL
and	NULL
h	NULL
)	NULL
.	NULL

This	NULL
band	NULL
is	NULL
not	NULL
competed	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
nonradioactive	NULL
oligonucleotide	NULL
and	NULL
is	NULL
not	NULL
specific	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
can	NULL
not	NULL
be	NULL
observed	NULL
after	NULL
Ficoll	NULL
purification	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
Fig	NULL
1C	NULL
,	NULL
compare	NULL
lanes	NULL
u	NULL
and	NULL
v	NULL
)	NULL
.	NULL

Nuclear	NULL
cell	NULL
extracts	NULL
from	NULL
patients	NULL
5	NULL
to	NULL
8	NULL
were	NULL
obtained	NULL
after	NULL
mononuclear	NULL
cell	NULL
purification	NULL
and	NULL
tested	NULL
in	NULL
bandshift	NULL
assays	NULL
with	NULL
the	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

Specific	NULL
DNA-binding	NULL
complexes	NULL
were	NULL
detected	NULL
with	NULL
all	NULL
cell	NULL
extracts	NULL
studied	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
DNA-binding	NULL
specificity	NULL
of	NULL
the	NULL
complexes	NULL
detected	NULL
with	NULL
leukemic	NULL
cell	NULL
extracts	NULL
.	NULL

The	NULL
DNA-binding	NULL
specificities	NULL
of	NULL
the	NULL
complexes	NULL
were	NULL
further	NULL
characterized	NULL
in	NULL
bandshift	NULL
competition	NULL
assays	NULL
by	NULL
using	NULL
the	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
and	NULL
nuclear	NULL
cell	NULL
extracts	NULL
from	NULL
patients	NULL
no	NULL
.	NULL

1	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
a	NULL
through	NULL
k	NULL
)	NULL
and	NULL
2	NULL
(	NULL
lanes	NULL
I	NULL
through	NULL
v	NULL
)	NULL
.	NULL

Various	NULL
GAS	NULL
elements	NULL
were	NULL
introduced	NULL
in	NULL
the	NULL
assay	NULL
as	NULL
competitors	NULL
.	NULL

The	NULL
results	NULL
show	NULL
that	NULL
the	NULL
DNA-binding	NULL
specificities	NULL
of	NULL
the	NULL
complexes	NULL
detected	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
are	NULL
different	NULL
.	NULL

The	NULL
DNA-binding	NULL
complexes	NULL
observed	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
were	NULL
competed	NULL
by	NULL
the	NULL
corresponding	NULL
cold	NULL
probe	NULL
(	NULL
lanes	NULL
b	NULL
and	NULL
m	NULL
)	NULL
,	NULL
but	NULL
also	NULL
by	NULL
APRE	NULL
(	NULL
lanes	NULL
j	NULL
and	NULL
u	NULL
)	NULL
and	NULL
by	NULL
GAS	NULL
elements	NULL
found	NULL
in	NULL
the	NULL
FeyRI	NULL
(	NULL
lanes	NULL
e	NULL
and	NULL
p	NULL
)	NULL
,	NULL
3-casein	NULL
(	NULL
lanes	NULL
f	NULL
and	NULL
q	NULL
)	NULL
,	NULL
and	NULL
FeeRIIb	NULL
(	NULL
lanes	NULL
g	NULL
and	NULL
r	NULL
)	NULL
gene	NULL
promoters	NULL
.	NULL

The	NULL
Ly-6E	NULL
oligonucleotide	NULL
showed	NULL
a	NULL
partial	NULL
competition	NULL
for	NULL
the	NULL
complex	NULL
formed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
no	NULL
.	NULL

1	NULL
(	NULL
lane	NULL
d	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
competition	NULL
is	NULL
complete	NULL
for	NULL
the	NULL
complex	NULL
detected	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
no	NULL
.	NULL

2	NULL
(	NULL
lane	NULL
0	NULL
)	NULL
.	NULL

The	NULL
same	NULL
observation	NULL
was	NULL
made	NULL
by	NULL
competition	NULL
with	NULL
SIE	NULL
m67	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
k	NULL
and	NULL
v	NULL
)	NULL
.	NULL

No	NULL
competition	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
GAS	NULL
element	NULL
from	NULL
the	NULL
guanylate	NULL
binding	NULL
protein	NULL
gene	NULL
(	NULL
GBP	NULL
)	NULL
promoter	NULL
(	NULL
lanes	NULL
i	NULL
and	NULL
t	NULL
)	NULL
and	NULL
the	NULL
ISRE	NULL
element	NULL
from	NULL
the	NULL
ISG-15	NULL
gene	NULL
promoter	NULL
(	NULL
lanes	NULL
c	NULL
and	NULL
n	NULL
)	NULL
.	NULL

The	NULL
competition	NULL
obtained	NULL
with	NULL
the	NULL
GAS	NULL
element	NULL
present	NULL
in	NULL
the	NULL
Ie	NULL
promoter	NULL
is	NULL
strong	NULL
but	NULL
not	NULL
complete	NULL
.	NULL

This	NULL
is	NULL
similar	NULL
for	NULL
the	NULL
extracts	NULL
from	NULL
both	NULL
&	NULL
m	NULL
haio	NULL
é	NULL
p	NULL
p	NULL
\	NULL
&	NULL
«	NULL
(	NULL
é-Qt	NULL
}	NULL
,	NULL
$	NULL
5006	NULL
?	NULL

§QQ	NULL
$	NULL
I	NULL
$	NULL
S	NULL
Pw	NULL
4s	NULL
Cy	NULL
o	NULL
'	NULL
y	NULL
9	NULL
Patient	NULL
n°*1	NULL
i	NULL
t	NULL
.~	NULL
Wiha	NULL
dhally	NULL
is	NULL
ins	NULL
a	NULL
b	NULL
c	NULL
d	NULL
e	NULL
f	NULL
g	NULL
h	NULL
i	NULL
Patient	NULL
n°2	NULL
I	NULL
m	NULL
n	NULL
o	NULL
p	NULL
gor	NULL
s	NULL
ot	NULL
u	NULL
v	NULL
Fig	NULL
2	NULL
.	NULL

Oligonucleotide	NULL
competition	NULL
for	NULL
DNA-complex	NULL
formation	NULL
with	NULL
distinct	NULL
subset	NULL
of	NULL
GAS	NULL
elements	NULL
.	NULL

Leukocyte	NULL
nuclear	NULL
extracts	NULL
from	NULL
patients	NULL
1	NULL
(	NULL
lanes	NULL
a	NULL
through	NULL
k	NULL
)	NULL
and	NULL
2	NULL
(	NULL
lanes	NULL
|	NULL
through	NULL
v	NULL
)	NULL
were	NULL
analyzed	NULL
in	NULL
bandshift	NULL
assays	NULL
with	NULL
the	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
in	NULL
presence	NULL
of	NULL
various	NULL
GAS	NULL
elements	NULL
.	NULL

The	NULL
indicated	NULL
oligonucleotides	NULL
were	NULL
used	NULL
in	NULL
competition	NULL
assays	NULL
in	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
as	NULL
indi-cated	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

STAT-RELATED	NULL
FACTORS	NULL
IN	NULL
ACUTE	NULL
LEUKEMIA	NULL
Patient	NULL
n°	NULL
1	NULL
-p	NULL
Patient	NULL
n°	NULL
2	NULL
g	NULL
hoi	NULL
j	NULL
k	NULL
|	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
DNA-protein	NULL
complexes	NULL
by	NULL
antibody	NULL
supershift	NULL
assays	NULL
.	NULL

Nuclear	NULL
cell	NULL
extracts	NULL
prepared	NULL
from	NULL
patients	NULL
no	NULL
.	NULL

1	NULL
and	NULL
2	NULL
were	NULL
incubated	NULL
without	NULL
(	NULL
lanes	NULL
a	NULL
and	NULL
g	NULL
)	NULL
or	NULL
with	NULL
anti-STAT1	NULL
,	NULL
-STAT2	NULL
,	NULL
-STAT3	NULL
(	NULL
C	NULL
)	NULL
,	NULL
-STAT4	NULL
,	NULL
-STAT5	NULL
specific	NULL
antisera	NULL
(	NULL
lanes	NULL
b	NULL
through	NULL
f	NULL
,	NULL
h	NULL
through	NULL
I	NULL
)	NULL
in	NULL
presence	NULL
of	NULL
IRF-1	NULL
radioactive	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

patients	NULL
(	NULL
lanes	NULL
h	NULL
and	NULL
s	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
STAT-related	NULL
factors	NULL
constitutively	NULL
activated	NULL
in	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
are	NULL
not	NULL
identical	NULL
.	NULL

STAT	NULL
!	NULL

-	NULL
,	NULL
STAT3-	NULL
,	NULL
and	NULL
STATS-related	NULL
factors	NULL
are	NULL
present	NULL
in	NULL
the	NULL
DNA-binding	NULL
complexes	NULL
.	NULL

_	NULL
We	NULL
examined	NULL
which	NULL
STAT	NULL
was	NULL
constitutively	NULL
activated	NULL
in	NULL
leukemic	NULL
cells	NULL
by	NULL
using	NULL
specific	NULL
antibodies	NULL
directed	NULL
against	NULL
STAT1	NULL
,	NULL
STAT2	NULL
,	NULL
STAT3	NULL
,	NULL
STAT4	NULL
,	NULL
and	NULL
STATS	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

Bandshift	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
ALL	NULL
(	NULL
no	NULL
.	NULL

1	NULL
)	NULL
and	NULL
with	NULL
AML	NULL
(	NULL
no	NULL
.	NULL

2	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
STAT-specific	NULL
antisera	NULL
.	NULL

The	NULL
complex	NULL
formed	NULL
with	NULL
the	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
ALL	NULL
(	NULL
no	NULL
.	NULL

1	NULL
)	NULL
,	NULL
associated	NULL
with	NULL
translocation	NULL
t	NULL
(	NULL
9,22	NULL
)	NULL
,	NULL
was	NULL
supershifted	NULL
by	NULL
STATS	NULL
antiserum	NULL
(	NULL
lane	NULL
f	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
STAT1	NULL
,	NULL
STAT2	NULL
,	NULL
STAT3	NULL
,	NULL
and	NULL
STAT4	NULL
antisera	NULL
(	NULL
lanes	NULL
b	NULL
through	NULL
e	NULL
)	NULL
.	NULL

The	NULL
DNA-binding	NULL
complex	NULL
formed	NULL
with	NULL
the	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
AML	NULL
patient	NULL
(	NULL
no	NULL
.	NULL

2	NULL
)	NULL
was	NULL
not	NULL
recognized	NULL
by	NULL
STAT1	NULL
,	NULL
STAT2	NULL
,	NULL
STAT4	NULL
,	NULL
and	NULL
STATS	NULL
antisera	NULL
(	NULL
lanes	NULL
h	NULL
,	NULL
i	NULL
,	NULL
k	NULL
,	NULL
and	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
DNA-binding	NULL
complex	NULL
formation	NULL
was	NULL
inhibited	NULL
with	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C	NULL
)	NULL
antiserum	NULL
(	NULL
lane	NULL
j	NULL
)	NULL
.	NULL

The	NULL
results	NULL
obtained	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
patients	NULL
3	NULL
to	NULL
8	NULL
and	NULL
STAT	NULL
antisera	NULL
are	NULL
presented	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

As	NULL
for	NULL
patient	NULL
no	NULL
.	NULL

1	NULL
,	NULL
the	NULL
complexes	NULL
formed	NULL
with	NULL
the	NULL
nuclear	NULL
proteins	NULL
from	NULL
patients	NULL
with	NULL
ALL	NULL
(	NULL
nos	NULL
.	NULL

3	NULL
and	NULL
8	NULL
)	NULL
were	NULL
supershifted	NULL
by	NULL
the	NULL
STATS	NULL
antiserum	NULL
.	NULL

This	NULL
antiserum	NULL
reacts	NULL
also	NULL
with	NULL
DNA-binding	NULL
complexes	NULL
from	NULL
patients	NULL
with	NULL
AML	NULL
nos	NULL
.	NULL

6	NULL
and	NULL
7	NULL
.	NULL

STAT3-related	NULL
factor	NULL
is	NULL
part	NULL
of	NULL
the	NULL
complexes	NULL
de-	NULL
1695	NULL
tected	NULL
in	NULL
all	NULL
patients	NULL
with	NULL
AML	NULL
(	NULL
nos	NULL
.	NULL

2	NULL
and	NULL
4-7	NULL
)	NULL
.	NULL

Supershift	NULL
of	NULL
the	NULL
DNA-binding	NULL
complex	NULL
formed	NULL
with	NULL
ALL	NULL
(	NULL
no	NULL
.	NULL

8	NULL
)	NULL
and	NULL
AML	NULL
(	NULL
no	NULL
.	NULL

6	NULL
)	NULL
occurred	NULL
in	NULL
presence	NULL
of	NULL
anti-STAT1	NULL
antibody	NULL
.	NULL

We	NULL
tested	NULL
three	NULL
antibodies	NULL
directed	NULL
against	NULL
different	NULL
parts	NULL
of	NULL
the	NULL
STAT3	NULL
protein	NULL
(	NULL
Fig	NULL
4A	NULL
)	NULL
.	NULL

DNA-binding	NULL
complexes	NULL
formed	NULL
with	NULL
the	NULL
IRF-1	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lane	NULL
a	NULL
)	NULL
and	NULL
nuclear	NULL
proteins	NULL
from	NULL
AML	NULL
patient	NULL
(	NULL
no	NULL
.	NULL

2	NULL
)	NULL
were	NULL
inhibited	NULL
by	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C	NULL
)	NULL
antiserum	NULL
(	NULL
lane	NULL
b	NULL
)	NULL
and	NULL
supershifted	NULL
by	NULL
the	NULL
anti-STAT3	NULL
(	NULL
30C	NULL
)	NULL
antiserum	NULL
(	NULL
lanes	NULL
c	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
antibody	NULL
recognition	NULL
was	NULL
obtained	NULL
with	NULL
the	NULL
complex	NULL
formed	NULL
by	NULL
the	NULL
proteins	NULL
from	NULL
AML	NULL
no	NULL
.	NULL

4	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

No	NULL
change	NULL
in	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
complex	NULL
was	NULL
detected	NULL
with	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C-20	NULL
)	NULL
antibody	NULL
(	NULL
lane	NULL
d	NULL
)	NULL
.	NULL

This	NULL
antibody	NULL
is	NULL
raised	NULL
against	NULL
the	NULL
amino	NULL
acids	NULL
750-769	NULL
of	NULL
the	NULL
carboxy	NULL
terminus	NULL
of	NULL
STAT3	NULL
and	NULL
recognizes	NULL
STAT3	NULL
factor	NULL
in	NULL
the	NULL
T47D	NULL
human	NULL
mammary	NULL
carcinoma	NULL
cell	NULL
line	NULL
treated	NULL
with	NULL
IL-6	NULL
for	NULL
15	NULL
min	NULL
(	NULL
Fig	NULL
4B	NULL
,	NULL
lane	NULL
f	NULL
)	NULL
.	NULL

The	NULL
anti-STAT3	NULL
(	NULL
C	NULL
)	NULL
and	NULL
the	NULL
anti-STAT3	NULL
(	NULL
3OC	NULL
)	NULL
antisera	NULL
are	NULL
respectively	NULL
directed	NULL
against	NULL
amino	NULL
acids	NULL
688	NULL
to	NULL
727	NULL
and	NULL
718	NULL
to	NULL
770	NULL
of	NULL
the	NULL
carboxy	NULL
terminus	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
STAT3-related	NULL
factor	NULL
in	NULL
the	NULL
AML	NULL
differs	NULL
in	NULL
the	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
C	NULL
terminus	NULL
from	NULL
the	NULL
previously	NULL
described	NULL
STAT3	NULL
protein	NULL
.	NULL

DISCUSSION	NULL
We	NULL
identified	NULL
constitutively	NULL
activated	NULL
DNA-binding	NULL
proteins	NULL
in	NULL
leukemic	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
ALL	NULL
and	NULL
AML	NULL
by	NULL
bandshift	NULL
analysis	NULL
.	NULL

The	NULL
competition	NULL
experiments	NULL
with	NULL
various	NULL
GAS	NULL
elements	NULL
,	NULL
able	NULL
to	NULL
bind	NULL
STAT	NULL
proteins	NULL
with	NULL
different	NULL
efficiency	NULL
,	NULL
show	NULL
the	NULL
existence	NULL
of	NULL
distinct	NULL
STAT	NULL
related	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
acute	NULL
leukemia	NULL
.	NULL

a	NULL
b	NULL
c	NULL
d	NULL
e	NULL
f	NULL
Fig	NULL
4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Supershift	NULL
assays	NULL
with	NULL
three	NULL
different	NULL
anti-STAT3	NULL
antibodies	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
AML	NULL
were	NULL
incubated	NULL
without	NULL
(	NULL
lane	NULL
a	NULL
)	NULL
or	NULL
with	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C	NULL
)	NULL
antiserum	NULL
(	NULL
lane	NULL
b	NULL
)	NULL
,	NULL
with	NULL
the	NULL
anti-STAT3	NULL
(	NULL
30C	NULL
)	NULL
antiserum	NULL
(	NULL
lane	NULL
c	NULL
)	NULL
and	NULL
with	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C-20	NULL
)	NULL
antibody	NULL
(	NULL
lane	NULL
d	NULL
)	NULL
in	NULL
presence	NULL
of	NULL
IRF-1	NULL
radioactive	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Nuclear	NULL
extracts	NULL
from	NULL
the	NULL
T47	NULL
D	NULL
human	NULL
mammary	NULL
carcinoma	NULL
cell	NULL
line	NULL
treated	NULL
with	NULL
IL-6	NULL
for	NULL
15	NULL
minutes	NULL
were	NULL
incubated	NULL
without	NULL
(	NULL
lane	NULL
e	NULL
)	NULL
or	NULL
with	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C-20	NULL
)	NULL
antibody	NULL
(	NULL
lane	NULL
f	NULL
)	NULL
in	NULL
presence	NULL
of	NULL
IRF-1	NULL
radioactive	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1696	NULL
A	NULL
distinct	NULL
pattern	NULL
of	NULL
competition	NULL
by	NULL
different	NULL
oligonucleotides	NULL
has	NULL
been	NULL
established	NULL
when	NULL
recombinant	NULL
STATS	NULL
protein	NULL
has	NULL
been	NULL
analyzed	NULL
in	NULL
bandshift	NULL
assays	NULL
.	NULL
``	NULL

An	NULL
identical	NULL
pattern	NULL
of	NULL
competition	NULL
was	NULL
found	NULL
when	NULL
the	NULL
proteins	NULL
from	NULL
ALL	NULL
cells	NULL
were	NULL
tested	NULL
.	NULL

This	NULL
strongly	NULL
suggests	NULL
that	NULL
STATS	NULL
or	NULL
a	NULL
closely	NULL
related	NULL
factor	NULL
is	NULL
activated	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

This	NULL
conclusion	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
the	NULL
DNA-binding	NULL
complex	NULL
was	NULL
supershifted	NULL
by	NULL
the	NULL
anti-STATS5	NULL
antiserum	NULL
.	NULL

A	NULL
protein	NULL
with	NULL
this	NULL
DNA-binding	NULL
specificity	NULL
is	NULL
also	NULL
induced	NULL
by	NULL
erythro-poietin	NULL
,	NULL
thrombopoietin	NULL
or	NULL
GM-CSF	NULL
in	NULL
UT7	NULL
cell	NULL
line	NULL
.	NULL
``	NULL

''	NULL
STATS5-related	NULL
factor	NULL
was	NULL
also	NULL
detected	NULL
in	NULL
two	NULL
of	NULL
five	NULL
patients	NULL
with	NULL
AML	NULL
.	NULL

Oligonucleotide	NULL
competition	NULL
and	NULL
recognition	NULL
by	NULL
anti-STAT3	NULL
antibodies	NULL
indicate	NULL
that	NULL
in	NULL
M1	NULL
,	NULL
M4	NULL
,	NULL
and	NULL
MS	NULL
AML	NULL
,	NULL
STAT3	NULL
is	NULL
part	NULL
of	NULL
the	NULL
DNA-protein	NULL
complex	NULL
.	NULL

The	NULL
use	NULL
of	NULL
three	NULL
slightly	NULL
different	NULL
antibodies	NULL
demonstrates	NULL
that	NULL
the	NULL
STAT3-related	NULL
proteins	NULL
present	NULL
in	NULL
AML	NULL
differ	NULL
in	NULL
their	NULL
C	NULL
terminus	NULL
from	NULL
the	NULL
described	NULL
STAT3	NULL
transcription	NULL
factor	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
a	NULL
highly	NULL
related	NULL
STAT3	NULL
factor	NULL
,	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
STAT	NULL
5a	NULL
and	NULL
STATSb	NULL
,	NULL
``	NULL
°**	NULL
``	NULL
or	NULL
splice	NULL
variants	NULL
of	NULL
STAT3	NULL
protein	NULL
,	NULL
as	NULL
described	NULL
for	NULL
STATla	NULL
and	NULL
STAT1P	NULL
,	NULL
``	NULL
have	NULL
been	NULL
detected	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
short	NULL
form	NULL
of	NULL
STAT3	NULL
,	NULL
was	NULL
identified	NULL
by	NULL
its	NULL
interaction	NULL
with	NULL
an	NULL
N-terminal	NULL
segment	NULL
of	NULL
c-jun	NULL
in	NULL
the	NULL
yeast	NULL
two-hybrid	NULL
screen	NULL
of	NULL
a	NULL
mammalian	NULL
cDNA	NULL
library	NULL
.	NULL

is	NULL
missing	NULL
the	NULL
55	NULL
C-terminal	NULL
amino	NULL
acid	NULL
residues	NULL
and	NULL
has	NULL
7	NULL
additional	NULL
amino	NULL
acid	NULL
residues	NULL
at	NULL
its	NULL
C	NULL
terminus	NULL
.	NULL
``	NULL

The	NULL
STAT3-related	NULL
protein	NULL
detected	NULL
in	NULL
AML	NULL
patients	NULL
might	NULL
be	NULL
related	NULL
to	NULL
STAT	NULL
33	NULL
.	NULL

However	NULL
,	NULL
another	NULL
explanation	NULL
for	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
the	NULL
three	NULL
anti-STAT3	NULL
antibodies	NULL
is	NULL
that	NULL
STAT3	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
a	NULL
complex	NULL
with	NULL
different	NULL
proteins	NULL
in	NULL
the	NULL
AML	NULL
cells	NULL
and	NULL
thus	NULL
the	NULL
epitope	NULL
recognized	NULL
by	NULL
the	NULL
anti-STAT3	NULL
(	NULL
C-20	NULL
)	NULL
antibody	NULL
is	NULL
not	NULL
available	NULL
to	NULL
be	NULL
recognized	NULL
by	NULL
this	NULL
antibody	NULL
.	NULL

Supershift	NULL
experiments	NULL
with	NULL
the	NULL
various	NULL
anti-STAT	NULL
antibodies	NULL
showed	NULL
that	NULL
STAT	NULL
i-related	NULL
factor	NULL
is	NULL
also	NULL
constitutively	NULL
activated	NULL
in	NULL
some	NULL
patients	NULL
with	NULL
ALL	NULL
or	NULL
AML	NULL
.	NULL

STAT	NULL
DNA-binding	NULL
occurred	NULL
without	NULL
the	NULL
in	NULL
vitro	NULL
stimulation	NULL
of	NULL
the	NULL
cells	NULL
before	NULL
nuclear	NULL
protein	NULL
extraction	NULL
.	NULL

These	NULL
proteins	NULL
need	NULL
to	NULL
be	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
before	NULL
they	NULL
translocate	NULL
to	NULL
nucleus	NULL
and	NULL
bind	NULL
to	NULL
DNA	NULL
.	NULL
``	NULL

This	NULL
implies	NULL
that	NULL
the	NULL
STAT	NULL
proteins	NULL
detected	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
ALL	NULL
and	NULL
AML	NULL
cells	NULL
are	NULL
tyrosine	NULL
phosphorylated	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
antiphosphotyrosine	NULL
antibody	NULL
in	NULL
the	NULL
bandshift	NULL
assays	NULL
leads	NULL
to	NULL
a	NULL
decrease	NULL
of	NULL
the	NULL
DNA-complex	NULL
formation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
results	NULL
might	NULL
indicate	NULL
that	NULL
the	NULL
tyrosine	NULL
kinase	NULL
responsible	NULL
for	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT	NULL
proteins	NULL
is	NULL
activated	NULL
.	NULL

STAT	NULL
proteins	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
the	NULL
substrates	NULL
of	NULL
the	NULL
JAK	NULL
tyrosine	NULL
kinases	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
recently	NULL
that	NULL
a	NULL
mutation	NULL
of	NULL
the	NULL
hopTum-1	NULL
gene	NULL
,	NULL
the	NULL
Drosophila	NULL
homolog	NULL
of	NULL
JAK	NULL
kinase	NULL
causes	NULL
leukemia-like	NULL
hematopoietic	NULL
defects	NULL
.	NULL
``	NULL

This	NULL
mutation	NULL
leads	NULL
to	NULL
the	NULL
constitutive	NULL
activity	NULL
of	NULL
the	NULL
protein	NULL
.	NULL
``	NULL

Identification	NULL
of	NULL
target	NULL
genes	NULL
induced	NULL
by	NULL
constitutively	NULL
activated	NULL
JAK	NULL
in	NULL
Drosophila	NULL
and	NULL
activated	NULL
STAT	NULL
proteins	NULL
in	NULL
human	NULL
leukemic	NULL
cells	NULL
will	NULL
be	NULL
of	NULL
great	NULL
interest	NULL
.	NULL

Constitutively	NULL
activated	NULL
STAT	NULL
proteins	NULL
have	NULL
also	NULL
been	NULL
observed	NULL
in	NULL
human	NULL
breast	NULL
tumors	NULL
``	NULL
and	NULL
in	NULL
mice	NULL
with	NULL
an	NULL
onco-transgene	NULL
.	NULL
``	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
STAT	NULL
proteins	NULL
become	NULL
activated	NULL
in	NULL
ALL	NULL
and	NULL
AML	NULL
cells	NULL
is	NULL
not	NULL
known	NULL
.	NULL

The	NULL
production	NULL
GOUILLEUX-GRUART	NULL
ET	NULL
AL	NULL
of	NULL
cytokines	NULL
and	NULL
growth	NULL
factors	NULL
by	NULL
leukemic	NULL
cells	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
differential	NULL
activation	NULL
of	NULL
STAT	NULL
proteins	NULL
in	NULL
acute	NULL
leukemia	NULL
.	NULL

ALL	NULL
and	NULL
AML	NULL
are	NULL
divided	NULL
in	NULL
various	NULL
subtypes	NULL
characterized	NULL
by	NULL
the	NULL
lineage	NULL
and	NULL
the	NULL
degree	NULL
of	NULL
maturation	NULL
of	NULL
the	NULL
cells	NULL
involved	NULL
in	NULL
the	NULL
leukemia	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
activation	NULL
of	NULL
other	NULL
STAT	NULL
members	NULL
is	NULL
implicated	NULL
in	NULL
the	NULL
other	NULL
subtypes	NULL
depending	NULL
on	NULL
cell	NULL
differentiation	NULL
,	NULL
maturation	NULL
,	NULL
and	NULL
cytokine	NULL
production	NULL
.	NULL

Another	NULL
mechanism	NULL
of	NULL
constitutive	NULL
activation	NULL
of	NULL
STAT	NULL
proteins	NULL
could	NULL
be	NULL
a	NULL
bypass	NULL
of	NULL
cytokine	NULL
receptors	NULL
by	NULL
an	NULL
oncogenic	NULL
pathway	NULL
.	NULL

Recently	NULL
,	NULL
an	NULL
enhanced	NULL
DNA-binding	NULL
activity	NULL
of	NULL
a	NULL
STAT3-related	NULL
protein	NULL
has	NULL
been	NULL
described	NULL
in	NULL
cells	NULL
transformed	NULL
by	NULL
the	NULL
Src	NULL
oncoprotein	NULL
.	NULL
``	NULL

The	NULL
participation	NULL
of	NULL
the	NULL
strong	NULL
BCR-ABL	NULL
kinase	NULL
activity	NULL
resulting	NULL
from	NULL
the	NULL
translocation	NULL
t	NULL
(	NULL
9,22	NULL
)	NULL
``	NULL
*	NULL
``	NULL
can	NULL
be	NULL
envisaged	NULL
in	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
STAT	NULL
proteins	NULL
in	NULL
leukemia	NULL
associated	NULL
with	NULL
the	NULL
Ph	NULL
chromosome	NULL
.	NULL

Jak-STAT	NULL
signaling	NULL
is	NULL
induced	NULL
by	NULL
the	NULL
v-ab/	NULL
oncogene	NULL
.	NULL
``	NULL

These	NULL
data	NULL
might	NULL
explain	NULL
the	NULL
strong	NULL
STATS	NULL
constitutive	NULL
activation	NULL
observed	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
Ph	NULL
'	NULL
positive	NULL
ALL	NULL
and	NULL
in	NULL
the	NULL
K562	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Our	NULL
findings	NULL
that	NULL
constitutive	NULL
activation	NULL
of	NULL
STATI	NULL
,	NULL
STAT3	NULL
,	NULL
and	NULL
STATS	NULL
occurs	NULL
in	NULL
cells	NULL
from	NULL
acute	NULL
leukemia	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
STAT	NULL
signaling	NULL
pathway	NULL
regulates	NULL
expression	NULL
of	NULL
cellular	NULL
genes	NULL
that	NULL
participate	NULL
to	NULL
leukemogenesis	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Dr	NULL
D.	NULL
Levy	NULL
for	NULL
providing	NULL
the	NULL
anti-STAT3	NULL
(	NULL
30C	NULL
)	NULL
antiserum	NULL
.	NULL

We	NULL
thank	NULL
Dr	NULL
J.	NULL
Darnell	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
anti-STAT2	NULL
,	NULL
anti-STAT3	NULL
(	NULL
C	NULL
)	NULL
and	NULL
anti-STAT4	NULL
antisera	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Darnell	NULL
JE	NULL
,	NULL
Kerr	NULL
IM	NULL
,	NULL
Stark	NULL
GR	NULL
:	NULL
JAK-STAT	NULL
pathways	NULL
and	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
IFNs	NULL
and	NULL
other	NULL
extracellular	NULL
signaling	NULL
proteins	NULL
.	NULL

Science	NULL
264:1415	NULL
,	NULL
1994	NULL
2	NULL
.	NULL

Thile	NULL
JN	NULL
,	NULL
Witthuhn	NULL
BA	NULL
,	NULL
Quelle	NULL
FW	NULL
,	NULL
Yamamoto	NULL
K	NULL
,	NULL
Thierfelder	NULL
WE	NULL
,	NULL
Kreider	NULL
B	NULL
,	NULL
Silvennoinen	NULL
O	NULL
:	NULL
Signaling	NULL
by	NULL
the	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
:	NULL
JAKs	NULL
and	NULL
STATs	NULL
.	NULL

Trends	NULL
Biochem	NULL
Sci	NULL
19	NULL
;	NULL
222	NULL
,	NULL
1994	NULL
3	NULL
.	NULL

Wilks	NULL
AF	NULL
,	NULL
Harpur	NULL
AG	NULL
:	NULL
Cytokine	NULL
signal	NULL
transduction	NULL
and	NULL
the	NULL
JAK	NULL
family	NULL
of	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Bioessays	NULL
16:313	NULL
,	NULL
1994	NULL
4	NULL
.	NULL

Briscoe	NULL
J	NULL
,	NULL
Guschin	NULL
D	NULL
,	NULL
Miiller	NULL
M	NULL
:	NULL
Just	NULL
another	NULL
signaling	NULL
pathway	NULL
.	NULL

Curr	NULL
Biol	NULL
41033	NULL
,	NULL
1994	NULL
5	NULL
.	NULL

Taniguchi	NULL
T	NULL
:	NULL
Cytokine	NULL
signaling	NULL
through	NULL
non	NULL
receptor	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Science	NULL
268:251	NULL
,	NULL
1995	NULL
6	NULL
.	NULL

Shuai	NULL
K	NULL
,	NULL
Schindler	NULL
C	NULL
,	NULL
Prezioso	NULL
VR	NULL
,	NULL
Darnell	NULL
JE	NULL
:	NULL
Activation	NULL
of	NULL
transcription	NULL
by	NULL
IFN-y	NULL
:	NULL
Tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
91-kD	NULL
DNA-binding	NULL
protein	NULL
.	NULL

Science	NULL
259:1808	NULL
,	NULL
1992	NULL
7	NULL
.	NULL

Schindler	NULL
C	NULL
,	NULL
Fu	NULL
XY	NULL
,	NULL
Improta	NULL
T	NULL
,	NULL
Aebersold	NULL
R	NULL
,	NULL
Darnell	NULL
JE	NULL
:	NULL
Proteins	NULL
of	NULL
transcription	NULL
factor	NULL
ISGF-3	NULL
:	NULL
One	NULL
gene	NULL
encodes	NULL
the	NULL
91-and	NULL
84-kDa	NULL
ISGF-3	NULL
proteins	NULL
that	NULL
are	NULL
activated	NULL
by	NULL
interferon	NULL
a.	NULL
Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:7836	NULL
,	NULL
1992	NULL
8	NULL
.	NULL

Fu	NULL
XY	NULL
,	NULL
Schindler	NULL
C	NULL
,	NULL
Improta	NULL
T	NULL
,	NULL
Aebersold	NULL
R	NULL
,	NULL
Darnell	NULL
JE	NULL
:	NULL
The	NULL
proteins	NULL
of	NULL
ISGF-3	NULL
,	NULL
the	NULL
interferon	NULL
alpha-induced	NULL
transcriptional	NULL
activator	NULL
,	NULL
define	NULL
a	NULL
gene	NULL
family	NULL
involved	NULL
in	NULL
signal	NULL
transduction	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:7840	NULL
,	NULL
1992	NULL
9	NULL
.	NULL

Zhong	NULL
Z	NULL
,	NULL
Wen	NULL
Z	NULL
,	NULL
Darnell	NULL
JE	NULL
:	NULL
Stat3	NULL
:	NULL
A	NULL
STAT	NULL
family	NULL
member	NULL
activated	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
response	NULL
to	NULL
epidermal	NULL
growth	NULL
factor	NULL
and	NULL
interleukin-6	NULL
.	NULL

Science	NULL
264:95	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Akira	NULL
S	NULL
,	NULL
Nishio	NULL
Y	NULL
,	NULL
Inoue	NULL
M	NULL
,	NULL
Wang	NULL
X-J	NULL
,	NULL
Wei	NULL
S	NULL
,	NULL
Matsusaka	NULL
T	NULL
,	NULL
Yoshida	NULL
K	NULL
,	NULL
Sudo	NULL
T	NULL
,	NULL
Naruto	NULL
M	NULL
,	NULL
Kishimoto	NULL
T	NULL
:	NULL
Molecular	NULL
cloning	NULL
of	NULL
APREF	NULL
,	NULL
a	NULL
novel	NULL
IFN-stimulated	NULL
gene	NULL
factor	NULL
3	NULL
p91	NULL
-related	NULL
transcrip-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

STAT-RELATED	NULL
FACTORS	NULL
IN	NULL
ACUTE	NULL
LEUKEMIA	NULL
tion	NULL
factor	NULL
involved	NULL
in	NULL
the	NULL
gp130-mediated	NULL
signaling	NULL
pathway	NULL
.	NULL

Cell	NULL
77:63	NULL
,	NULL
1994	NULL
11	NULL
.	NULL

Jacobson	NULL
NG	NULL
,	NULL
Szabo	NULL
Sj	NULL
,	NULL
Weber-Nordt	NULL
RM	NULL
,	NULL
Zhong	NULL
Z	NULL
,	NULL
Schreiber	NULL
RD	NULL
,	NULL
Darnell	NULL
JE	NULL
,	NULL
Murphy	NULL
KM	NULL
:	NULL
Interleukin	NULL
12	NULL
signaling	NULL
in	NULL
T	NULL
helper	NULL
type	NULL
1	NULL
(	NULL
Th1	NULL
)	NULL
cells	NULL
involves	NULL
tyrosine	NULL
phosphrylation	NULL
of	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
Stat	NULL
)	NULL
3	NULL
and	NULL
Stat4	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
181:1755	NULL
,	NULL
1995	NULL
12	NULL
.	NULL

Tian	NULL
S-S8	NULL
,	NULL
Lamb	NULL
P	NULL
,	NULL
Seidel	NULL
MH	NULL
,	NULL
Stein	NULL
RB	NULL
,	NULL
Rosen	NULL
J	NULL
:	NULL
Rapid	NULL
activation	NULL
of	NULL
the	NULL
Stat3	NULL
transcription	NULL
factor	NULL
by	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
.	NULL

Blood	NULL
84:1760	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

Yamamoto	NULL
K	NULL
,	NULL
Quelle	NULL
FW	NULL
,	NULL
Thierfelder	NULL
WE	NULL
,	NULL
Kreider	NULL
BL	NULL
,	NULL
Gilbert	NULL
DJ	NULL
,	NULL
Jenkins	NULL
NA	NULL
,	NULL
Copeland	NULL
NG	NULL
,	NULL
Silvennoinen	NULL
O	NULL
,	NULL
Thile	NULL
JN	NULL
:	NULL
STATA	NULL
,	NULL
a	NULL
novel	NULL
gamma	NULL
interferon	NULL
activation	NULL
site-binding	NULL
protein	NULL
expressed	NULL
in	NULL
early	NULL
myeloid	NULL
differentiation	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:4342	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Wakao	NULL
H	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Groner	NULL
B	NULL
:	NULL
Mammary	NULL
gland	NULL
factor	NULL
(	NULL
MGF	NULL
)	NULL
is	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
cytokine	NULL
regulated	NULL
transcription	NULL
factor	NULL
gene	NULL
family	NULL
and	NULL
confers	NULL
the	NULL
prolactin	NULL
response	NULL
.	NULL

EMBO	NULL
J	NULL
13:2182	NULL
,	NULL
1994	NULL
15	NULL
.	NULL

Gouilleux	NULL
F	NULL
,	NULL
Pallard	NULL
C	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
Haldosen	NULL
L-A	NULL
,	NULL
Norstedt	NULL
G	NULL
,	NULL
Levy	NULL
D	NULL
,	NULL
Groner	NULL
B	NULL
:	NULL
Prolactin	NULL
,	NULL
growth	NULL
hormone	NULL
,	NULL
erythropoietin	NULL
and	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
induce	NULL
MGF-STAT53	NULL
DNA-binding	NULL
activity	NULL
.	NULL

EMBO	NULL
J	NULL
14:2005	NULL
,	NULL
1995	NULL
16	NULL
.	NULL

Wood	NULL
TJ	NULL
,	NULL
Sliva	NULL
D	NULL
,	NULL
Lobie	NULL
PE	NULL
,	NULL
Pircher	NULL
TJ	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
Gustafsson	NULL
J-A	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Norstedt	NULL
G	NULL
,	NULL
Haldosén	NULL
L-A	NULL
:	NULL
Mediation	NULL
of	NULL
growth	NULL
hormone-dependent	NULL
transcriptional	NULL
activation	NULL
by	NULL
mammary	NULL
gland	NULL
factor/STATS5	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:9448	NULL
,	NULL
1995	NULL
17	NULL
.	NULL

Pallard	NULL
C	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Benit	NULL
L	NULL
,	NULL
Cocault	NULL
L	NULL
,	NULL
Souyri	NULL
M	NULL
,	NULL
Levy	NULL
D	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
:	NULL
Thrombopoietin	NULL
activates	NULL
a	NULL
STATS5-like	NULL
factor	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
14:2847	NULL
,	NULL
1995	NULL
18	NULL
.	NULL

Gaffen	NULL
SL	NULL
,	NULL
Lai	NULL
SY	NULL
,	NULL
Xu	NULL
W	NULL
,	NULL
Gouilleux	NULL
F.	NULL
Groner	NULL
B	NULL
,	NULL
Goldsmith	NULL
MA	NULL
,	NULL
Greene	NULL
WC	NULL
:	NULL
Signaling	NULL
through	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
3	NULL
chain	NULL
activates	NULL
a	NULL
STAT	NULL
5-like	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:7192	NULL
,	NULL
1995	NULL
19	NULL
.	NULL

Wakao	NULL
H	NULL
,	NULL
Harada	NULL
N	NULL
,	NULL
Kitamura	NULL
T	NULL
,	NULL
Mui	NULL
ALF	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
Interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
and	NULL
erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
activate	NULL
STATS/MGF	NULL
via	NULL
distinct	NULL
pathways	NULL
.	NULL

EMBO	NULL
J	NULL
14:2527	NULL
,	NULL
1995	NULL
20	NULL
.	NULL

Mui	NULL
ALF	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
O'Farrell	NULL
AM	NULL
,	NULL
Harada	NULL
N	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
Interleukin-3	NULL
,	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
and	NULL
interleukin-5	NULL
transduce	NULL
signals	NULL
through	NULL
two	NULL
STATS	NULL
homologs	NULL
.	NULL

EMBO	NULL
J	NULL
14:1166	NULL
,	NULL
1995	NULL
21	NULL
.	NULL

Azam	NULL
M	NULL
,	NULL
Erdjument-Bromage	NULL
H	NULL
,	NULL
Kreider	NULL
BL	NULL
,	NULL
Xia	NULL
M	NULL
,	NULL
Quelle	NULL
F	NULL
,	NULL
Basu	NULL
R	NULL
,	NULL
Saris	NULL
C	NULL
,	NULL
Tempst	NULL
P	NULL
,	NULL
Ihle	NULL
JN	NULL
,	NULL
Schindler	NULL
C	NULL
:	NULL
Interleukin-3	NULL
signals	NULL
through	NULL
multiple	NULL
isoforms	NULL
of	NULL
Stat5	NULL
.	NULL

EMBO	NULL
J	NULL
14:1402	NULL
,	NULL
1995	NULL
22	NULL
.	NULL

Liu	NULL
X	NULL
,	NULL
Robinson	NULL
GW	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Hennighausen	NULL
1697	NULL
L	NULL
:	NULL
Cloning	NULL
and	NULL
expression	NULL
of	NULL
STATS	NULL
and	NULL
an	NULL
additional	NULL
homologue	NULL
(	NULL
STATS5b	NULL
)	NULL
involved	NULL
in	NULL
prolactin	NULL
signal	NULL
transduction	NULL
in	NULL
mouse	NULL
mammary	NULL
tissue	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:8831	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

Hou	NULL
J	NULL
,	NULL
Schindler	NULL
U	NULL
,	NULL
Henzel	NULL
WJ	NULL
,	NULL
Ho	NULL
TC	NULL
,	NULL
Brasseur	NULL
M	NULL
,	NULL
McKnight	NULL
SL	NULL
:	NULL
An	NULL
interleukin-4-induced	NULL
transcription	NULL
factor	NULL
:	NULL
IL-4	NULL
Stat	NULL
.	NULL

Science	NULL
265:1701	NULL
,	NULL
1994	NULL
24	NULL
.	NULL

Quelle	NULL
FW	NULL
,	NULL
Shimoda	NULL
K	NULL
,	NULL
Thierfelder	NULL
W	NULL
,	NULL
Fischer	NULL
C	NULL
,	NULL
Kim	NULL
A	NULL
,	NULL
Ruben	NULL
SM	NULL
,	NULL
Cleveland	NULL
JI	NULL
,	NULL
Pierce	NULL
JH	NULL
,	NULL
Keegan	NULL
AD	NULL
,	NULL
Nelms	NULL
K	NULL
,	NULL
Paul	NULL
WE	NULL
,	NULL
Ihle	NULL
JN	NULL
:	NULL
Cloning	NULL
of	NULL
murine	NULL
STAT6	NULL
and	NULL
human	NULL
STAT6	NULL
,	NULL
STAT	NULL
proteins	NULL
that	NULL
are	NULL
tyrosine	NULL
phosphorylated	NULL
in	NULL
responses	NULL
to	NULL
IL4	NULL
and	NULL
IL3	NULL
but	NULL
are	NULL
not	NULL
required	NULL
for	NULL
mitogenesis	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
15:3336	NULL
,	NULL
1995	NULL
25	NULL
.	NULL

Luo	NULL
H	NULL
,	NULL
Hanratty	NULL
WP	NULL
,	NULL
Dearolf	NULL
CR	NULL
:	NULL
An	NULL
amino	NULL
acid	NULL
substitution	NULL
in	NULL
the	NULL
Drosophilia	NULL
hop	NULL
``	NULL
JAK	NULL
kinase	NULL
causes	NULL
leukemia-like	NULL
hematopoietic	NULL
defects	NULL
.	NULL

EMBO	NULL
J	NULL
14:1412	NULL
,	NULL
1995	NULL
26	NULL
.	NULL

Harrison	NULL
DA	NULL
,	NULL
Binari	NULL
R	NULL
,	NULL
Nabreini	NULL
TS	NULL
,	NULL
Gilman	NULL
M	NULL
,	NULL
Perrimon	NULL
N	NULL
:	NULL
Activation	NULL
of	NULL
a	NULL
Drosophilia	NULL
Janus	NULL
kinase	NULL
(	NULL
JAK	NULL
)	NULL
causes	NULL
hematopoietic	NULL
neoplasia	NULL
and	NULL
developmental	NULL
defects	NULL
.	NULL

EMBO	NULL
J	NULL
14:2857	NULL
,	NULL
1995	NULL
27	NULL
.	NULL

Migone	NULL
T-S	NULL
,	NULL
Lin	NULL
J-X	NULL
,	NULL
Cereseto	NULL
A	NULL
,	NULL
Mulloy	NULL
JC	NULL
,	NULL
O'Shea	NULL
JJ	NULL
,	NULL
Franchini	NULL
G	NULL
,	NULL
Leonard	NULL
W	NULL
:	NULL
Constitutively	NULL
activated	NULL
JAK-STAT	NULL
pathway	NULL
in	NULL
T	NULL
cells	NULL
transformed	NULL
with	NULL
HTLV-1	NULL
.	NULL

Science	NULL
269:79	NULL
,	NULL
1995	NULL
28	NULL
.	NULL

Benett	NULL
JM	NULL
,	NULL
Catovski	NULL
D	NULL
,	NULL
Daniel	NULL
M-T	NULL
,	NULL
Flandrin	NULL
G	NULL
,	NULL
Galton	NULL
DAG	NULL
,	NULL
Gralnick	NULL
HR	NULL
,	NULL
Sultan	NULL
C	NULL
:	NULL
Proposal	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
the	NULL
acute	NULL
leukemia	NULL
(	NULL
FAB	NULL
cooperation	NULL
group	NULL
)	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
33:451	NULL
,	NULL
1976	NULL
29	NULL
.	NULL

Schaefer	NULL
TS	NULL
,	NULL
Sanders	NULL
LK	NULL
,	NULL
Nathans	NULL
D	NULL
:	NULL
Cooperative	NULL
transcriptional	NULL
activity	NULL
of	NULL
Jun	NULL
and	NULL
Stat3	NULL
$	NULL
,	NULL
a	NULL
short	NULL
form	NULL
of	NULL
Stat3	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:9097	NULL
,	NULL
1995	NULL
30	NULL
.	NULL

Watson	NULL
CJ	NULL
,	NULL
Millet	NULL
WR	NULL
:	NULL
Elevated	NULL
levels	NULL
of	NULL
Stat	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
breast	NULL
carcinoma	NULL
nuclear	NULL
extracts	NULL
.	NULL

Br	NULL
J	NULL
Cancer	NULL
71:840	NULL
,	NULL
1995	NULL
31	NULL
.	NULL

Happ	NULL
B	NULL
,	NULL
Hynes	NULL
NE	NULL
,	NULL
Groner	NULL
B	NULL
:	NULL
Ha-ras	NULL
and	NULL
v-raf	NULL
,	NULL
but	NULL
not	NULL
int-2	NULL
and	NULL
c-myc	NULL
,	NULL
interfere	NULL
with	NULL
the	NULL
lactogenic	NULL
hormone	NULL
dependent	NULL
activation	NULL
of	NULL
the	NULL
mammary	NULL
gland	NULL
specific	NULL
transcription	NULL
factor	NULL
MGF	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
4:9	NULL
,	NULL
1993	NULL
32	NULL
.	NULL

Yu	NULL
C-L	NULL
,	NULL
Meyer	NULL
DJ	NULL
,	NULL
Campbell	NULL
GS	NULL
,	NULL
Larner	NULL
AC	NULL
,	NULL
Carter-Su	NULL
C	NULL
,	NULL
Schwartz	NULL
J	NULL
,	NULL
Jove	NULL
R	NULL
:	NULL
Enhanced	NULL
DNA-binding	NULL
activity	NULL
of	NULL
a	NULL
Stat3-related	NULL
protein	NULL
in	NULL
cells	NULL
transformed	NULL
by	NULL
the	NULL
Src	NULL
oncoprotein	NULL
.	NULL

Science	NULL
269:81	NULL
,	NULL
1995	NULL
33	NULL
.	NULL

Konopka	NULL
JB	NULL
,	NULL
Watanabe	NULL
SM	NULL
,	NULL
Witte	NULL
ON	NULL
:	NULL
An	NULL
alteration	NULL
of	NULL
the	NULL
human	NULL
c-abl	NULL
protein	NULL
in	NULL
K562	NULL
leukemia	NULL
cells	NULL
unmasks	NULL
associated	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
.	NULL

Cell	NULL
37:1035	NULL
,	NULL
1984	NULL
34	NULL
.	NULL

Lu	NULL
D	NULL
,	NULL
Liu	NULL
J	NULL
,	NULL
Campbell	NULL
M	NULL
,	NULL
Guo	NULL
JQ	NULL
,	NULL
Heisterkamp	NULL
N	NULL
,	NULL
Groffen	NULL
J	NULL
,	NULL
Canaai	NULL
E	NULL
,	NULL
Arlinghaus	NULL
R	NULL
:	NULL
Tyrosine	NULL
phosphorylation	NULL
of	NULL
P160	NULL
BCR	NULL
by	NULL
P210	NULL
BCR-ABL	NULL
.	NULL

Blood	NULL
82:1257	NULL
,	NULL
1993	NULL
35	NULL
.	NULL

Danial	NULL
NN	NULL
,	NULL
Pernis	NULL
A	NULL
,	NULL
Rothman	NULL
PB	NULL
:	NULL
Jak-STAT	NULL
signaling	NULL
induced	NULL
by	NULL
the	NULL
v-abl	NULL
oncogene	NULL
.	NULL

Science	NULL
269:1875	NULL
,	NULL
1995	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1996	NULL
87	NULL
:	NULL
1692-1697	NULL
STAT-related	NULL
transcription	NULL
factors	NULL
are	NULL
constitutively	NULL
activated	NULL
in	NULL
peripheral	NULL
blood	NULL
cells	NULL
from	NULL
acute	NULL
leukemia	NULL
patients	NULL
V	NULL
Gouilleux-Gruart	NULL
,	NULL
F	NULL
Gouilleux	NULL
,	NULL
C	NULL
Desaint	NULL
,	NULL
JF	NULL
Claisse	NULL
,	NULL
JC	NULL
Capiod	NULL
,	NULL
J	NULL
Delobel	NULL
,	NULL
R	NULL
Weber-Nordt	NULL
,	NULL
|	NULL
Dusanter-Fourt	NULL
,	NULL
F	NULL
Dreyfus	NULL
,	NULL
B	NULL
Groner	NULL
and	NULL
L	NULL
Prin	NULL
4	NULL
QM	NULL
“	NULL
Caw	NULL
,	NULL
.	NULL

,	NULL
'	NULL
\se	NULL
@	NULL
.	NULL

2	NULL
YOtow®	NULL
@	NULL
207	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/87/5/1692.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

